DUBRF yields 22727.27% · JNJ yields 2.14%● Live data
📍 DUBRF pulled ahead of the other in Year 1
Combined, DUBRF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DUBRF + JNJ for your $10,000?
Dubber Corporation Limited provides unified call recording and voice intelligence cloud solutions worldwide. It offers Dubber You, a tool to search, play, edit, organize, and share conversations from any device; Dubber Teams that capture all conversations for managers and leaders needing central review and control over accurate recordings and data; Dubber Premier, a conversational intelligence tool; Dubber Compliance Editions for compliance teams and managers; and Voice Intelligence Cloud platform. The company also provides Dubber CallN that unified conversational data and recording - automating, analyzing, and distributing insights on customer conversations, agent performance, quality assurance, and others; Dubber Speik that provides secure PCI compliance and call recording; Notes by Dubber, an AI Notetaker that automatically generates transcripts, action items, and rich summaries from calls and meetings; and Dubber PCI for service providers and Amazon Connect. It serves, enterprises, small and medium businesses, financial services, government, education, healthcare, and legal sectors, as well as for service and solution providers. The company was formerly known as Crucible Gold Limited and changed its name to Dubber Corporation Limited in December 2014. Dubber Corporation Limited was incorporated in 1999 and is headquartered in Melbourne, Australia.
Full DUBRF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.